BioAssets Development Corporation (BDC) is pioneering novel indications for marketed and emerging biologic drugs. The Company's lead initiative focuses on the development of cytokine inhibitors to treat the underlying causes of pain in spinal disorders. BDC offers customized collaborations tailored to maximize the value of partners' core strategic assets by expanding the indications of successful biologic drugs.
Download Corporate Factsheet

Recent News & Events:

  • 10.26.09 | Cephalon Signs Option  Agreement to Acquire BioAssets... More
  • 07.30.07 | BioAssets Completes $5.4 Million Financing ... More
  • 12.25.06 | BioAssets: Convergence as Marketing Play ... More